– PRGN-2009 combined with an investigational checkpoint inhibitor resulted in a 30% ORR in patients with heavily pre-treated HPV-associated cancers that were naïve or resistant to checkpoint...

-- Breadth of pipeline featured in multiple early clinical data presentations, reflecting diversity of fundamental growth drivers across development programs -- CAMBRIDGE, Mass., June 3, 2023...

Initial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2, with a well-tolerated safety profile Elevation...

Compared To Synthetic Controls, INT230-6 Alone Extended Survival In Refractory Soft Tissue Sarcoma Subjects by Nearly 450 Days With Favorable Safety INT230-6, a Locally Delivered Cytotoxic...

-- Patricia Mae Garcia Santos, MD, MS, receives annual Conquer Cancer-Women Leaders in Oncology "Women Who Conquer Cancer" Young Investigator Award -- -- Tafadzwa L. Chaunzwa, MD, MHS, receives...